CluePoints wins prestigious accolade for commitment to innovation and education

21 Nov 2023
www.outsourcing-pharma.com
The award was presented at The Dorchester in London, on Thursday last week (November 16), and the company reports it was made in recognition of its innovative solutions, its high-quality relationships with partners and clients, and its commitment to advancing the sector’s knowledge and expertise in RBQM.
The category, for CROs that provide niche services, was judged on achievements made between June 2022 and June 2023.
Some of the world’s leading RBQM voices came together at CluePoint’s RBQMLive conference which was both organized and sponsored by the company. The event saw major discussions on how to adopt and implement an efficiency-saving, safety-enhancing approach to clinical trial design and delivery.
It also partnered with the Tufts Center for the Study of Drug Development (Tufts CSDD) on a global survey of more than 125 pharma, biopharma and CROs on current RBQM adoption patterns.
Data-driven approach
Phastar continued working with the FDA, through a Cooperative Research and Development Agreement (CRADA), to develop a data-driven approach to site inspection, prioritization, and selection.
And on top of that it launched a machine learning (ML) algorithm to streamline medical coding, and a deep learning (DL) model to automatically identify discrepancies and anomalies in adverse event and medication data with up to 96% precision.
François Torche, co-founder and chief product and technology officer at CluePoints, said: “We are thrilled that our work to further the adoption of RBQM across the industry, and the high-quality innovative solutions and services we provide our customers, has been recognized by the esteemed Scrip Awards team. Winning this award really is an honor, especially when considering the amazing company’s we were shortlisted alongside.
googletag.cmd.push(function () {
googletag.display('text-ad1');
});
“I would like to thank all the CluePoints staff who have worked tirelessly to make the organization what it is today. We will continue our efforts to lead the industry in its RBQM adoption and innovation through our education offerings, our partnerships, and our pioneering technology.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.